Trial Profile
A 24 Month, Randomized, Controlled, Study to Evaluate the Efficacy and Safety of Concentration-controlled Everolimus Plus Reduced Tacrolimus Compared to Standard Tacrolimus in Recipients of Living Donor Liver Transplants and Long Term Extension to Evaluate the Efficacy and Safety of Concentration-controlled Everolimus Plus Reduced Tacrolimus Compared to Standard Tacrolimus in Recipients of Living Donor Liver Transplants in Japan
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Corticosteroids; Tacrolimus
- Indications Liver transplant rejection
- Focus Registrational; Therapeutic Use
- Sponsors Novartis; Novartis Healthcare; Novartis Pharma KK; Novartis Pharmaceuticals
- 15 Nov 2021 Results of pooled analysis from two global pivotal clinical trials (H2304 [NCT00622869] and H2307 [NCT01888432] presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases
- 13 Nov 2018 Results of a pooled analysis from H2304 and H2307 studies, presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
- 06 Jun 2018 24-Month results presented at the 2018 American Transplant Congress